Get advice on Virginia buttonweed and knotweed control, shade alternatives to St. Augustine, oak bark issues and willow borer ...

While most grasses go dormant or pause growth in the winter, not all weeds do - but which ones are most prevalent depends on ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the U.S. Food ...

Nuvalent will discuss the data for TKI pre-treated ALK-positive NSCLC patients with the FDA in a pre-NDA meeting ...

New federal testing data shows that reading scores of teens in the U.S. are lower than they have been in decades.

The FDA accepted a new drug application for zidesamtinib for previously treated locally advanced or metastatic ROS1-positive ...

After years of volatility, crop protection is stabilizing. Discover where recovery, regulation, and innovation are reshaping ...

Zidesamtinib targets ROS1+ NSCLC patients with prior TKI treatment, addressing CNS-penetrant treatment challenges and ...

NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of September 18, 2026 CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ ...

People and organizations often pay a hefty price when they pivot beyond their typical area of focus, according to Kellogg ...

Background Percutaneous ventricular assist devices (pVAD) have been increasingly used to support haemodynamics during ...

Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena.